Companies
8-K ↗8-K ↗
RVMD
Revolution Medicines, Inc.
Revolution Medicines develops drug candidates targeting RAS and other oncology-related pathways. The pipeline is in preclinical and clinical development stages, with efforts focused on discovering and advancing product candidates through regulatory approval processes. The organization is pursuing multiple indications and relies on collaborations and licensing arrangements to support its research and development operations.
$144.12+256.91%1Y
RVMD · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 2Colorectal Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2Advanced Solid Tumors
Phase 2Metastatic Solid Tumors
Phase 2Colorectal Cancer (CRC)
Phase 2CRC
Phase 3NSCLC (Non-small Cell Lung Cancer)
Phase 3NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 3Pancreatic Cancer
Phase 3Pancreatic Cancer Metastatic
Phase 3PDAC
Phase 3PDAC - Pancreatic Ductal Adenocarcinoma
Phase 3Pancreatic Adenocarcinoma Metastatic
Phase 3Pancreatic Adenosquamous Carcinoma
Phase 3Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3Resected Pancreatic Adenocarcinoma
Phase 2Non-Small Cell Lung Cancer
Phase 3NSCLC (Non-small Cell Lung Cancer)
Phase 3Non-Small Cell Lung Cancer
Phase 3NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 3Pancreatic Cancer
Phase 3PDAC
Phase 3PDAC - Pancreatic Ductal Adenocarcinoma
Phase 2Colorectal Cancer
Phase 2CRC
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2Gastrointestinal Cancer
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma
Phase 3Pancreatic Cancer Metastatic
Phase 3Pancreatic Adenocarcinoma Metastatic
Phase 3Pancreatic Adenosquamous Carcinoma
Phase 3Pancreatic Cancer
Phase 3PDAC
Phase 3PDAC - Pancreatic Ductal Adenocarcinoma
Phase 3Pancreatic Cancer
Phase 3PDAC
Phase 3PDAC - Pancreatic Ductal Adenocarcinoma
Phase 2Colorectal Cancer
Phase 2CRC
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2Gastrointestinal Cancer
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma
Phase 3Pancreatic Cancer Metastatic
Phase 3Pancreatic Adenocarcinoma Metastatic
Phase 3Pancreatic Adenosquamous Carcinoma
Phase 2KRAS, NRAS, HRAS-mutated NSCLC
Phase 2KRAS G12C-mutated Solid Tumors, Lung Cancer
Phase 2Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
Phase 2RAS G12D-mutated NSCLC
Phase 3Pancreatic Cancer
Phase 3PDAC
Phase 3PDAC - Pancreatic Ductal Adenocarcinoma
Phase 2Colorectal Cancer (CRC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Advanced Solid Tumors
Phase 2Colorectal Cancer
Phase 2CRC
Phase 2Gastrointestinal Cancer
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2Non-Small Cell Lung Cancer
Phase 2Colorectal Cancer
Phase 2CRC
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2PDAC
Phase 2Gastrointestinal Cancer
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2KRAS, NRAS, HRAS-mutated NSCLC
Phase 2KRAS G12C-mutated Solid Tumors, Lung Cancer
Phase 2Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
Phase 2RAS G12D-mutated NSCLC
Phase 2Non-Small Cell Lung Cancer
Phase 2Advanced Solid Tumors
Phase 2Metastatic Solid Tumors
Phase 2Colorectal Cancer (CRC)
Phase 2CRC
Phase 2Non-Small Cell Lung Cancer
Phase 2Advanced Solid Tumors
Phase 2Metastatic Solid Tumors
Phase 2Colorectal Cancer (CRC)
Phase 2CRC
Phase 2Non-Small Cell Lung Cancer
Phase 2Colorectal Cancer
Phase 2CRC
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2PDAC
Phase 2Gastrointestinal Cancer
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2Advanced Solid Tumors
Phase 2Metastatic Solid Tumors
Phase 2Colorectal Cancer (CRC)
Phase 2CRC
Phase 2Non-Small Cell Lung Cancer
Phase 2KRAS, NRAS, HRAS-mutated NSCLC
Phase 2KRAS G12C-mutated Solid Tumors, Lung Cancer
Phase 2Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
Phase 2RAS G12D-mutated NSCLC
Phase 2Non-Small Cell Lung Cancer
Phase 2Advanced Solid Tumors
Phase 2Metastatic Solid Tumors
Phase 2Colorectal Cancer (CRC)
Phase 2CRC
Phase 2Non-Small Cell Lung Cancer
Phase 2Colorectal Cancer
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2Advanced Solid Tumors
Phase 2Metastatic Solid Tumors
Phase 2Colorectal Cancer (CRC)
Phase 2CRC
Phase 2Non-Small Cell Lung Cancer
Phase 2Advanced Solid Tumors
Phase 2Metastatic Solid Tumors
Phase 2Colorectal Cancer (CRC)
Phase 2CRC
Phase 2Non-Small Cell Lung Cancer
Phase 2Colorectal Cancer
Phase 2CRC
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2PDAC
Phase 2Gastrointestinal Cancer
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2Colorectal Cancer
Phase 2CRC
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2PDAC
Phase 2Gastrointestinal Cancer
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2KRAS, NRAS, HRAS-mutated NSCLC
Phase 2KRAS G12C-mutated Solid Tumors, Lung Cancer
Phase 2Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
Phase 2RAS G12D-mutated NSCLC
Phase 2Non-Small Cell Lung Cancer
Phase 2KRAS, NRAS, HRAS-mutated NSCLC
Phase 2KRAS G12C-mutated Solid Tumors, Lung Cancer
Phase 2Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
Phase 2RAS G12D-mutated NSCLC
Phase 2Non-Small Cell Lung Cancer
Phase 2KRAS, NRAS, HRAS-mutated NSCLC
Phase 2KRAS G12C-mutated Solid Tumors, Lung Cancer
Phase 2Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
Phase 2RAS G12D-mutated NSCLC
Phase 2Non-Small Cell Lung Cancer
Phase 2KRAS, NRAS, HRAS-mutated NSCLC
Phase 2KRAS G12C-mutated Solid Tumors, Lung Cancer
Phase 2Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
Phase 2RAS G12D-mutated NSCLC
Phase 2Colorectal Cancer
Phase 2CRC
Phase 2Pancreatic Ductal Adenocarcinoma
Phase 2PDAC
Phase 2Gastrointestinal Cancer
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2Non-Small Cell Lung Cancer
Phase 2Advanced Solid Tumors
Phase 2Metastatic Solid Tumors
Phase 2Colorectal Cancer (CRC)
Phase 2CRC
Phase 2Non-Small Cell Lung Cancer
Catalyst Calendar
Past (2)
H2
Enroll.RMC-6236
“The Company continues to anticipate initiating the RASolute 302 study in the second half of 2024.”
APR 13
ReadoutDaraxonrasib
“On April 13, 2026, Revolution Medicines, Inc. (the "Company") shared topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") who had been previously treated.”